TWI832854B - 丁苯那嗪經皮輸送裝置 - Google Patents

丁苯那嗪經皮輸送裝置 Download PDF

Info

Publication number
TWI832854B
TWI832854B TW108114349A TW108114349A TWI832854B TW I832854 B TWI832854 B TW I832854B TW 108114349 A TW108114349 A TW 108114349A TW 108114349 A TW108114349 A TW 108114349A TW I832854 B TWI832854 B TW I832854B
Authority
TW
Taiwan
Prior art keywords
tetrabenazine
adhesive composition
adhesive
transdermal delivery
delivery device
Prior art date
Application number
TW108114349A
Other languages
English (en)
Chinese (zh)
Other versions
TW202014187A (zh
Inventor
蘇雷許 波爾沙迪亞
卡爾帕納 帕特爾
福成 陳
Original Assignee
美商神經治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商神經治療股份有限公司 filed Critical 美商神經治療股份有限公司
Publication of TW202014187A publication Critical patent/TW202014187A/zh
Application granted granted Critical
Publication of TWI832854B publication Critical patent/TWI832854B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108114349A 2018-04-25 2019-04-24 丁苯那嗪經皮輸送裝置 TWI832854B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662456P 2018-04-25 2018-04-25
US62/662,456 2018-04-25

Publications (2)

Publication Number Publication Date
TW202014187A TW202014187A (zh) 2020-04-16
TWI832854B true TWI832854B (zh) 2024-02-21

Family

ID=68295781

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108114349A TWI832854B (zh) 2018-04-25 2019-04-24 丁苯那嗪經皮輸送裝置

Country Status (15)

Country Link
US (2) US12144899B2 (enExample)
EP (1) EP3784237B1 (enExample)
JP (1) JP7386544B2 (enExample)
KR (1) KR102952482B1 (enExample)
CN (1) CN112165942B (enExample)
AU (1) AU2019261403B2 (enExample)
BR (1) BR112020021700A2 (enExample)
CA (1) CA3097189A1 (enExample)
DK (1) DK3784237T3 (enExample)
ES (1) ES2968827T3 (enExample)
IL (1) IL278185B2 (enExample)
MX (1) MX2020011269A (enExample)
TW (1) TWI832854B (enExample)
WO (1) WO2019209940A1 (enExample)
ZA (1) ZA202006415B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
US20220362165A1 (en) * 2019-10-22 2022-11-17 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
EP4125902A4 (en) * 2020-03-30 2024-05-22 Shinkei Therapeutics, Inc. TRANSDERMAL ADMINISTRATION OF DEXTROMETHORPHAN
CN116036055A (zh) * 2023-03-16 2023-05-02 上海世领制药有限公司 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078604A1 (en) * 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
CN106456629A (zh) * 2014-05-06 2017-02-22 纽罗克里生物科学有限公司 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313723A (ja) * 1987-06-16 1988-12-21 Nitto Electric Ind Co Ltd 外用貼付剤
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP4988080B2 (ja) * 1997-09-05 2012-08-01 日東電工株式会社 経皮吸収型製剤
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US9056060B2 (en) * 2000-09-19 2015-06-16 Henkel Ag & Co. Kgaa Non-reactive adhesive useful in transdermal drug delivery system
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
AU2013243461A1 (en) * 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
EP2872126B1 (en) * 2012-07-16 2017-12-06 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
EP2999444A4 (en) * 2013-05-20 2016-10-12 Mylan Inc ADVANCED TRANSDERMAL DOSAGE OF PRAMIPEXOL FOR THE TREATMENT OF NEUROLOGICAL DISEASES
AP2015008920A0 (en) * 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system
EP3398602A1 (en) 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CN106061506A (zh) 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
KR20240125709A (ko) 2015-06-23 2024-08-19 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
CN107028916B (zh) * 2016-02-04 2020-05-12 北京泰德制药股份有限公司 含有布比卡因或其药用盐的皮肤外用制剂
ITUB20161016A1 (it) * 2016-02-24 2017-08-24 Emenem Srl Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
CN110678181A (zh) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
EP3395336A1 (en) * 2017-04-28 2018-10-31 Nitto Denko Corporation Transdermal absorption preparation
EP3664787B1 (en) 2017-07-20 2022-07-20 Neurolixis Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
GB2565049B (en) 2017-07-27 2020-06-10 Reckitt Benckiser Health Ltd A head assembly of a dermaplaning device
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
US20190374521A1 (en) 2018-06-10 2019-12-12 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078604A1 (en) * 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
CN106456629A (zh) * 2014-05-06 2017-02-22 纽罗克里生物科学有限公司 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Also Published As

Publication number Publication date
MX2020011269A (es) 2020-12-11
US12144899B2 (en) 2024-11-19
JP7386544B2 (ja) 2023-11-27
DK3784237T3 (da) 2024-01-08
EP3784237A1 (en) 2021-03-03
KR102952482B1 (ko) 2026-04-13
WO2019209940A1 (en) 2019-10-31
US20250144045A1 (en) 2025-05-08
ZA202006415B (en) 2024-04-24
AU2019261403A1 (en) 2020-11-12
EP3784237A4 (en) 2022-02-16
TW202014187A (zh) 2020-04-16
JP2021522240A (ja) 2021-08-30
AU2019261403B2 (en) 2025-05-15
US20210128490A1 (en) 2021-05-06
ES2968827T3 (es) 2024-05-14
IL278185B1 (en) 2024-07-01
IL278185B2 (en) 2024-11-01
CN112165942B (zh) 2024-04-12
CN112165942A (zh) 2021-01-01
IL278185A (enExample) 2020-12-31
EP3784237B1 (en) 2023-11-01
CA3097189A1 (en) 2019-10-31
KR20210005623A (ko) 2021-01-14
BR112020021700A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
US20250144045A1 (en) Tetrabenazine transdermal delivery device
KR101737960B1 (ko) 외용 의약 조성물
KR101032282B1 (ko) 첩부제
JP4261911B2 (ja) 貼付剤
TW201521796A (zh) 用於經皮傳遞三級胺藥物之組合物及方法
TW200300095A (en) Plaster having laminated support
JP7709432B2 (ja) テトラベナジン経皮送達デバイス
RU2800536C2 (ru) Устройство для трансдермальной доставки тетрабеназина
RU2838380C1 (ru) Устройство для трансдермальной доставки тетрабеназина
HK40042329A (en) Tetrabenazine transdermal delivery device
HK40042329B (zh) 丁苯那嗪透皮输送装置
KR20200006065A (ko) 루파타딘-함유 패치
HK40081373A (en) Tetrabenazine transdermal delivery device
WO2018104772A1 (ja) 経皮吸収型製剤
JP2022532635A (ja) 高含量のドネペジル又はその塩を含む経皮吸収製剤
WO2020189323A1 (ja) 薬物の生体への吸収性に優れ、且つ、化学的安定性にも優れる医薬組成物